20.10
0.54%
-0.11
After Hours:
20.105
0.005
+0.02%
Overview
News
Price History
Option Chain
Why FMS Down?
Discussions
Forecast
Stock Split
Dividend History
Fresenius Medical Care AG & Co. KGaA ADR stock is currently priced at $20.10, with a 24-hour trading volume of 305.42K.
It has seen a -0.54% decreased in the last 24 hours and a +6.29% rose in the past month.
The chart indicates a potential bearish trend, as the stock is below the $20.26 pivot point. If it approaches the $20.05 support level, significant changes may occur.
Previous Close:
$20.21
Open:
$20.09
24h Volume:
305.42K
Market Cap:
$11.80B
Revenue:
$21.06B
Net Income/Loss:
$540.03M
P/E Ratio:
24.64
EPS:
0.8156
Net Cash Flow:
$2.10B
1W Performance:
+2.87%
1M Performance:
+6.29%
6M Performance:
+21.38%
1Y Performance:
-13.14%
Fresenius Medical Care AG & Co. KGaA ADR Stock (FMS) Company Profile
Name
Fresenius Medical Care AG & Co. KGaA ADR
Sector
Industry
Phone
49 6172 609 0
Address
Else-Kröner Strasse 1, Bad Homburg
Fresenius Medical Care AG & Co. KGaA ADR Stock (FMS) Upgrades & Downgrades
Date | Action | Analyst | Rating Change |
---|---|---|---|
Jan-08-24 | Downgrade | Morgan Stanley | Equal-Weight → Underweight |
Nov-24-23 | Upgrade | HSBC Securities | Reduce → Hold |
Nov-17-23 | Upgrade | Societe Generale | Hold → Buy |
Aug-14-23 | Downgrade | UBS | Buy → Neutral |
Aug-01-23 | Resumed | Citigroup | Neutral |
Jul-12-23 | Initiated | Goldman | Buy |
Mar-07-23 | Initiated | Bernstein | Mkt Perform |
Jan-03-23 | Downgrade | Jefferies | Buy → Underperform |
Oct-26-22 | Downgrade | Deutsche Bank | Hold → Sell |
Oct-18-22 | Initiated | Morgan Stanley | Equal-Weight |
Oct-10-22 | Downgrade | Jefferies | Buy → Hold |
Jun-27-22 | Upgrade | Jefferies | Underperform → Buy |
Feb-11-22 | Downgrade | Jefferies | Hold → Underperform |
Nov-23-21 | Initiated | HSBC Securities | Hold |
Nov-11-21 | Upgrade | Jefferies | Underperform → Hold |
Feb-04-21 | Downgrade | JP Morgan | Overweight → Neutral |
Feb-03-21 | Downgrade | Deutsche Bank | Buy → Hold |
Aug-05-20 | Downgrade | Jefferies | Buy → Hold |
May-20-20 | Upgrade | Morgan Stanley | Underweight → Equal-Weight |
Jan-21-20 | Upgrade | Jefferies | Hold → Buy |
Jun-20-19 | Upgrade | Barclays | Equal Weight → Overweight |
Dec-10-18 | Downgrade | Morgan Stanley | Overweight → Equal-Weight |
Oct-26-18 | Upgrade | UBS | Neutral → Buy |
Aug-28-18 | Upgrade | HSBC Securities | Hold → Buy |
Jul-05-18 | Downgrade | Credit Suisse | Outperform → Neutral |
Jan-04-18 | Upgrade | UBS | Sell → Neutral |
Dec-11-17 | Downgrade | Morgan Stanley | Overweight → Equal-Weight |
Nov-01-16 | Reiterated | RBC Capital Mkts | Sector Perform |
Sep-06-16 | Upgrade | Citigroup | Neutral → Buy |
Jul-08-16 | Upgrade | Jefferies | Underperform → Hold |
Jan-04-16 | Upgrade | JP Morgan | Neutral → Overweight |
Nov-04-15 | Reiterated | RBC Capital Mkts | Sector Perform |
Sep-03-15 | Upgrade | Goldman | Neutral → Buy |
Aug-13-15 | Downgrade | Societe Generale | Buy → Hold |
Jul-31-15 | Reiterated | RBC Capital Mkts | Sector Perform |
Aug-02-13 | Reiterated | Feltl & Co. | Hold |
Jan-14-13 | Upgrade | HSBC Securities | Neutral → Overweight |
View All
Fresenius Medical Care AG & Co. KGaA ADR Stock (FMS) Latest News
Comfort Systems USA and Boeing have been highlighted as Zacks Bull and Bear of the Day
Zacks Investment Research
3 Medical Device Stocks With Solid Dividend Yield: CAH & Others
Zacks Investment Research
Reasons to Retain Fresenius Medical (FMS) in Your Portfolio Now
Zacks Investment Research
Inogen (INGN) Up 26.6% Since Last Earnings Report: Can It Continue?
Zacks Investment Research
Paragon 28, Inc. (FNA) Moves 16.2% Higher: Will This Strength Last?
Zacks Investment Research
Fresenius Medical (FMS) to Unveil Training on Augmented Reality
Zacks Investment Research
Fresenius Medical Care AG & Co. KGaA ADR Stock (FMS) Financials Data
Fresenius Medical Care AG & Co. KGaA ADR (FMS) Revenue 2024
FMS reported a revenue (TTM) of $21.06 billion for the quarter ending December 31, 2023, a +3.17% rise year-over-year.
Fresenius Medical Care AG & Co. KGaA ADR (FMS) Net Income 2024
FMS net income (TTM) was $540.03 million for the quarter ending December 31, 2023, a -23.62% decrease year-over-year.
Fresenius Medical Care AG & Co. KGaA ADR (FMS) Cash Flow 2024
FMS recorded a free cash flow (TTM) of $2.10 billion for the quarter ending December 31, 2023, a +38.28% increase year-over-year.
Fresenius Medical Care AG & Co. KGaA ADR (FMS) Earnings per Share 2024
FMS earnings per share (TTM) was $0.9199 for the quarter ending December 31, 2023, a -23.49% decline year-over-year.
About Fresenius Medical Care AG & Co. KGaA ADR
Fresenius Medical Care AG & Co. KGaA, a kidney dialysis company, provides dialysis care and related services, and other health care services. It offers dialysis treatment and related laboratory and diagnostic services through a network of outpatient dialysis clinics; materials, training, and patient support services comprising clinical monitoring, follow-up assistance, and arranging for delivery of the supplies to the patient's residence; and dialysis services under contract to hospitals in the United States for the hospitalized end-stage renal disease (ESRD) patients and for patients suffering from acute kidney failure. The company also develops, manufactures, and distributes dialysis products, including hemodialysis machines, peritoneal cyclers, dialyzers, peritoneal solutions, hemodialysis concentrates, solutions and granulates, bloodlines, renal pharmaceuticals, and water treatment systems for the treatment of ESRD; offers renal medications and supplies to patients at homes or to dialysis clinics; and provides vascular, cardiovascular, endovascular specialty, hospitalist and intensivist, medical cost management, ambulatory surgery center, health plan, urgent care, physician nephrology and cardiology, and ambulant treatment services. In addition, it develops, acquires, and in-licenses renal pharmaceuticals; and offers non-dialysis products, including acute cardiopulmonary and apheresis products. The company sells its products to clinics, hospitals, and specialized treatment clinics directly, as well as through local sales forces, independent distributors, dealers, and sales agents. As of December 31, 2017, it operated 3,752 outpatient dialysis clinics in approximately 50 countries. The company has operations in Germany, the United States, and internationally. Fresenius Medical Care AG & Co. KGaA was founded in 1996 and is headquartered in Bad Homburg, Germany.
Cap:
|
Volume (24h):